⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341976 | 0.76 | — | — | |
| SCHEMBL12206804 | 0.71 | — | — | |
| SCHEMBL2419624 | 0.65 | — | — | |
| SCHEMBL14257868 | 0.59 | — | — | |
| SCHEMBL12472458 | 0.59 | — | — | |
| SCHEMBL545707 | 0.57 | — | — | |
| SCHEMBL17175152 | 0.57 | TSHR (0.31) | — | |
| SCHEMBL8552421 | 0.57 | — | — | |
| SCHEMBL20403837 | 0.56 | TSHR (0.39) | — | |
| SCHEMBL2473194 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20200255468-A1 | MODIFIED NUCLEOSIDE PHOSPHORAMIDITES | Janssen Pharmaceuticals, Inc. | 2020-08-13 | — | — | US | disclosed |
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2017-09-28 | — | — | US | disclosed |
| WO-2016041877-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2016-03-24 | — | — | WO | disclosed |
| US-8470988-B2 | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |